(c) 2024 PillSync.com

venlafaxine 75 MG Oral Tablet

INDICATIONS AND USAGE Venlafaxine tablets, USP are indicated for the treatment of major depressive disorder. The efficacy of venlafaxine tablets, USP in the treatment of major depressive disorder was established in 6 week controlled trials of adult outpatients whose diagnoses corresponded most closely to the DSM-III or DSM-III-R category of major depression and in a 4 week controlled trial of inpatients meeting diagnostic criteria for major depression with melancholia (see CLINICAL TRIALS ). A major depressive episode implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigue, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and a suicide attempt or suicidal ideation. The efficacy of venlafaxine hydrochloride extended-release capsules in maintaining an antidepressant response for up to 26 weeks following 8 weeks of acute treatment was demonstrated in a placebo-controlled trial. The efficacy of venlafaxine tablets in maintaining an antidepressant response in patients with recurrent depression who had responded and continued to be improved during an initial 26 weeks of treatment and were then followed for a period of up to 52 weeks was demonstrated in a second placebo-controlled trial (see CLINICAL TRIALS ). Nevertheless, the physician who elects to use venlafaxine tablets/venlafaxine hydrochloride extended-release capsules for extended periods should periodically re-evaluate the long-term usefulness of the drug for the individual patient.

Zydus Pharmaceuticals (USA) Inc.


5 years ago ROUND ORANGE ZC 67 venlafaxine 75 MG Oral Tablet

ROUND ORANGE ZC 67

5 years ago ROUND ORANGE ZC 67 venlafaxine 75 MG Oral Tablet

ZC 67 ROUND ORANGE

HOW SUPPLIED

VENLAFAXINE Tablets, USP equivalent to 25 mg of

VENLAFAXINE are peach-colored, round, flat, beveled-edged tablets with bisect on one side; one side of bisect is debossed with logo of "ZC" and other side is debossed with "64" and other side is plain and are supplied as follows: NDC 68382-018-06 in bottles of 30 tablets with child-resistant closure NDC 68382-018-14 in bottles of 60 tablets with child-resistant closure NDC 68382-018-16 in bottles of 90 tablets with child-resistant closure NDC 68382-018-01 in bottles of 100 tablets NDC 68382-018-05 in bottles of 500 tablets NDC 68382-018-10 in bottles of 1000 tablets

VENLAFAXINE Tablets, USP equivalent to 37.5 mg of

VENLAFAXINE are peach-colored, round, flat, beveled-edged tablets with bisect on one side; one side of bisect is debossed with logo of "ZC" and other side is debossed with "65" and other side is plain and are supplied as follows: NDC 68382-019-06 in bottles of 30 tablets with child-resistant closure NDC 68382-019-14 in bottles of 60 tablets with child-resistant closure NDC 68382-019-16 in bottles of 90 tablets with child-resistant closure NDC 68382-019-01 in bottles of 100 tablets NDC 68382-019-05 in bottles of 500 tablets NDC 68382-019-10 in bottles of 1000 tablets

VENLAFAXINE Tablets, USP equivalent to 50 mg of

VENLAFAXINE are peach-colored, round, flat, beveled-edged tablets with bisect on one side; one side of the bisect is debossed with logo of "ZC" and other side is debossed with "66" and other side is plain and are supplied as follows: NDC 68382-020-06 in bottles of 30 tablets with child-resistant closure NDC 68382-020-14 in bottles of 60 tablets with child-resistant closure NDC 68382-020-16 in bottles of 90 tablets with child-resistant closure NDC 68382-020-01 in bottles of 100 tablets NDC 68382-020-05 in bottles of 500 tablets NDC 68382-020-10 in bottles of 1000 tablets

VENLAFAXINE Tablets, USP equivalent to 75 mg of

VENLAFAXINE are peach-colored, round, flat, beveled-edged tablets with bisect on one side; one side of the bisect is debossed with logo of "ZC" and other side is debossed with "67" and other side is plain and are supplied as follows: NDC 68382-021-06 in bottles of 30 tablets with child-resistant closure NDC 68382-021-14 in bottles of 60 tablets with child-resistant closure NDC 68382-021-16 in bottles of 90 tablets with child-resistant closure NDC 68382-021-01 in bottles of 100 tablets NDC 68382-021-05 in bottles of 500 tablets NDC 68382-021-10 in bottles of 1000 tablets

VENLAFAXINE Tablets, USP equivalent to 100 mg of

VENLAFAXINE are peach-colored, round, flat, beveled-edged tablets with bisect on one side; one side of the bisect is debossed with logo of "ZC" and other side is debossed with "68" and other side is plain and are supplied as follows: NDC 68382-101-06 in bottles of 30 tablets with child-resistant closure NDC 68382-101-14 in bottles of 60 tablets with child-resistant closure NDC 68382-101-16 in bottles of 90 tablets with child-resistant closure NDC 68382-101-01 in bottles of 100 tablets NDC 68382-101-05 in bottles of 500 tablets NDC 68382-101-10 in bottles of 1000 tablets Storage Store at 20°C to 25°C (68°F to 77°F) [See USP Controlled Room Temperature] in a dry place. Dispense in a well-closed container as defined in the USP. KEEP THIS AND ALL MEDICINES OUT OF THE REACH OF CHILDREN. Medication Guide available at www.zydususa.com/medguides or call 1-877-993-8779.


More pills like ROUND ZC 67












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site